Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2023 Mar 16;18(3):e0282791. doi: 10.1371/journal.pone.0282791

A new method for customized fetal growth reference percentiles

Katherine L Grantz 1,*, Stefanie N Hinkle 2, Dian He 1,3, John Owen 4, Daniel Skupski 5, Cuilin Zhang 1,6, Anindya Roy 7
Editor: Quetzal A Class8
PMCID: PMC10019672  PMID: 36928064

Abstract

Background

Customized fetal growth charts assume birthweight at term to be normally distributed across the population with a constant coefficient of variation at earlier gestational ages. Thus, standard deviation used for computing percentiles (e.g., 10th, 90th) is assumed to be proportional to the customized mean, although this assumption has never been formally tested.

Methods

In a secondary analysis of NICHD Fetal Growth Studies-Singletons (12 U.S. sites, 2009–2013) using longitudinal sonographic biometric data (n = 2288 pregnancies), we investigated the assumptions of normality and constant coefficient of variation by examining behavior of the mean and standard deviation, computed following the Gardosi method. We then created a more flexible model that customizes both mean and standard deviation using heteroscedastic regression and calculated customized percentiles directly using quantile regression, with an application in a separate study of 102, 012 deliveries, 37–41 weeks.

Results

Analysis of term optimal birthweight challenged assumptions of proportionality and that values were normally distributed: at different mean birthweight values, standard deviation did not change linearly with mean birthweight and the percentile computed with the normality assumption deviated from empirical percentiles. Composite neonatal morbidity and mortality rates in relation to birthweight < 10th were higher for heteroscedastic and quantile models (10.3% and 10.0%, respectively) than the Gardosi model (7.2%), although prediction performance was similar among all three (c-statistic 0.52–0.53).

Conclusions

Our findings question normality and constant coefficient of variation assumptions of the Gardosi customization method. A heteroscedastic model captures unstable variance in customization characteristics which may improve detection of abnormal growth percentiles.

Trial registration

ClinicalTrials.gov identifier: NCT00912132.

Introduction

Fetal undergrowth as often characterized by fetal growth restriction (FGR) and small-for-gestational age (SGA) is associated with an increased risk of perinatal morbidity and mortality [1]. SGA is often defined as birthweight < 10th percentile using a population based growth reference [2]. However, this approach identifies fetuses who are constitutionally small but otherwise healthy and misses fetuses who did not meet their growth potential but whose weight is at or above the 10th percentile. In 1992, Gardosi et al proposed a customized method for birthweight references that took into account six pregnancy characteristics known to influence birthweight and thought to be physiologic, namely gestational age, maternal pre-pregnancy weight, height, race, parity, and fetal sex [3]. This method was further extrapolated from birthweight to estimated fetal weight during gestation by using fetal ultrasonographic biometric data and a commonly used fetal growth reference from Hadlock [4, 5]. The percentiles for the ultrasound estimated fetal weight (EFW) curves (e.g., 10th, 50th and 90th) were proportionately adjusted upwards or downwards according to the Gardosi method’s expected optimal birthweight at term for a given set of maternal and fetal characteristics. Customized fetal growth references are appealing as they provide a more personalized definition of FGR and SGA, in line with a precision medicine approach; however, whether their use improves the clinical detection of fetuses with suboptimal growth and at risk of morbidity and mortality is controversial [68]. Nevertheless, they have been recommended for use by national guidelines in some countries including Britain, Ireland and New Zealand [9]. A recent randomized trial did not demonstrate improved prenatal detection of SGA using the Growth Assessment Protocol based on customized fetal growth charts compared to standard care, although the negative results have been questioned because of lack of adherence to the intervention study arm and bleeding of some parts of the intervention in the “standard care” arm [10, 11].

The primary metric of the Gardosi method is a customized term optimal birthweight (TOW) at 40 weeks which is then extrapolated to EFW at any gestational time using the proportionality model [12]. Based on the model and the proportionality assumption, the percentiles (e.g., 5th, 10th, 90th, 95th etc.) for the EFW are produced at all gestational ages between 24 and 42 weeks. However, the customized TOW percentiles are based on the assumptions that the distribution of birthweight is normal, and the standard deviation used for calculating the percentiles (e.g., 10th, 90th), is proportional to the mean, i.e., the coefficient of variation (CV) is constant; these assumptions have never been formally tested yet have important clinical implications, because different percentile cutoffs will identify different proportions of fetuses as SGA versus non-SGA. This differential classification would potentially increase the risk of stillbirth in those pregnancies where SGA goes undetected or cause unnecessary iatrogenic earlier delivery in pregnancies where SGA is erroneously diagnosed.

This study was a secondary analysis of the NICHD Fetal Growth Studies–Singletons, a prospective pregnancy cohort study with the primary aim to establish fetal growth standards for size and velocity in the U.S. [1315]. Our objectives were first, to evaluate the assumptions of the Gardosi customization model that the distribution of TOW around its customized mean value was normal and the standard deviation used for calculating the CV was proportional to the mean TOW. Second, we created a new customization method that has more flexibility in calculating customized percentiles using a heteroscedastic regression that customizes both mean TOW (and hence EFW by extrapolation) and standard deviation [16]. To be precise, the heteroscedastic model customizes a transformed value of the standard deviation but because that makes the standard deviation depend on the customizing factors, hereafter we refer to it as a model for customizing the standard deviation. Also, since clinical outcomes of SGA and LGA are essentially percentiles (e.g. 10th, 90th), we further customized fetal growth using quantile regression, which directly calculates the percentiles without being reliant on the model for the mean and the assumption of normality [17]. We compared the performance of all three customization methods in relation to SGA and LGA birthweight with neonatal morbidity and mortality within the NICHD Fetal Growth Study and also in a concurrent analysis from the Consortium on Safe Labor because it has a larger number of births.

Materials and methods

Study design and participants

The NICHD Fetal Growth Studies–Singletons recruited 2334 non-obese women (BMI 19·0–29·9 kg/m2) from four different race/ethnic groups who were non-smokers and had low-risk medical and obstetrical histories (e.g., no chronic diseases) from 2009 to 2013 at 12 U.S. centers. Details of recruitment and study design have been previously reported [18]. An additional 468 women with BMI 30·0–44·9 kg/m2 were recruited with similar inclusion criteria, although relaxed to allow certain chronic conditions (e.g. chronic hypertension controlled on medication), given the higher prevalence of concurrent morbidities with obesity [19]. Institutional review board approval was obtained at all participating sites as well as the NIH (IRB approval #09-CH-N152) on December 2009 prior to the study beginning. All participants provided written informed consent prior to data collection.

Procedures

Gestational age was based on a certain last menstrual period and confirmed by first trimester ultrasound [18]. At enrollment, information on demographics, obstetrical and medical histories, and lifestyle and health leading up to and during the first trimester of pregnancy was collected via in-person interview. After an enrollment sonogram at 10–13 weeks of gestation, women were randomly assigned to one of four ultrasound schedules for follow up visits at ranges 16–22, 24–29, 30–33, 34–37 and 38–41 weeks of gestation. For the assigned study visit, ± 1 week was allowed to accommodate women’s availability. Sonographers for the study underwent uniform, centralized training and credentialing. A standardized protocol was used to obtain ultrasound measurements for fetal biometry including head circumference (HC), abdominal circumference (AC), and femur length (FL) at each study visit using identical, high-resolution ultrasound units at each center. The HC, AC, and FL were used to calculate EFW using a Hadlock formula [20]. Information on lifestyle, reproductive and medical history were obtained via in-person interviews at each research visit. Demographic data and antenatal, labor, delivery and neonatal course and outcomes were abstracted from the prenatal record, labor and delivery summary, hospital and neonatal records by trained research personnel. Paternal height and weight were by maternal report.

Outcomes included SGA and LGA birthweight defined as < 10th or > 90th using the Duryea reference with neonatal morbidity and mortality [21]. Neonatal morbidities associated with SGA or LGA included: metabolic acidosis (pH <7.1 and base deficit >12mmol/L), neonatal intensive care unit (NICU) stay greater than three days, pneumonia, respiratory distress syndrome, persistent pulmonary hypertension, seizures, hyperbilirubinemia requiring exchange transfusion, intrapartum aspiration (meconium, amniotic fluid, blood), neonatal death, mechanical ventilation at term, necrotizing enterocolitis, hypoglycemia, hypoxic ischemic encephalopathy, periventricular leukomalacia (SGA only), sepsis based on blood culture (SGA only), bronchopulmonary dysplasia/chronic lung disease (SGA only), retinopathy of prematurity (SGA only), and birth injury (LGA only) [2226].

SGA and LGA associated with neonatal morbidities were defined similarly in a concurrent analysis of n = 102, 012 deliveries between 37–41 weeks from the Consortium on Safe Labor (CSL) [27]. Pregnancy, labor and delivery information was electronically abstracted from maternal records. Neonatal records included information on gestational age, NICU admission, medical conditions and discharge diagnoses. International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes were collected and linked to deliveries. Outcomes were defined to be consistent with previous CSL studies [28].

Statistical analysis

Demographic data were summarized as n (%) or mean (± SD). We developed a fetal growth percentile customization model using the Gardosi method [4]. Linear regression was used to predict birthweight at 40 weeks as the outcome, designated as the term optimal weight (TOW), using six customization variables: gestational age, maternal pre-pregnancy weight, height, race/ethnicity, parity, and infant sex. We then explored some of the assumptions of the Gardosi model, namely the assumption of normality and the constant CV assumption for the TOW distribution. If the Gardosi assumption of normality and constant CV were to hold, the percentiles computed based on Gardosi model should agree with the empirical percentiles across different levels of the mean birthweight. We stratified the estimated birthweight into eight contiguous intervals (depicting eight different values of mean birthweight) and investigated the agreement of the empirical percentiles with those obtained from the Gardosi model for each interval. To verify the assumption of constant CV, we looked at the relationship between the empirical standard deviation and the mean birthweight across the different birthweight intervals. As an extension to the Gardosi model which assumes that the standard deviation is proportional to the customized mean, we then created a model to customize both mean and standard deviation of the TOW using heteroscedastic regression with predicted birthweight at 40 weeks as the outcome and the same six customization variables [4]. The new customized mean and SD yielded customized values for the target percentiles using the quantile formula for normal distribution (S1 Table).

In a third customization model, we calculated customized percentiles directly using quantile regression with monotonic smoothing, a flexible model that does not assume a normal distribution [17]. Note that quantile regression customizes the target percentiles directly without using a 2-step model where first the customized mean and the customized standard deviation are obtained and then the percentiles are computed using the quantile formula for normal distribution. All three models included the same customizing variables containing cubic and quadratic terms of deviation of gestational time at delivery from the optimal 280 days mark a priori per the Gardosi model. In addition to the six proposed “physiological” variables that influence fetal growth, models also included “pathological” variables, smoking, BMI (kg/m2), and gestational diabetes, gestational hypertensive disease/preeclampsia, and antepartum bleeding. The analysis was centered on 280 days’ gestation, height 163 cm, pre-pregnancy weight 64 kg, nulliparous, and Non-Hispanic White race/ethnicity. However, only the coefficients for the six “physiologic” variables (as designated by the Gardosi method) were included in an additive model to calculate the TOW percentiles [12]. The six variables were categorized similar to the Gardosi model with some slight alterations due to the availability of the data. Specifically, we included four race/ethnic groups (Asian, Hispanic, Non-Hispanic Black, Non-Hispanic White) instead of ethnic origin which was not available in our study. Parity 2 and greater (P2+) was combined into one group because of sparse data for higher parity whereas the Gardosi model includes each one separately: P0 (ref), P1, P2, P3, P > = 4. Standard goodness-of-fit and model diagnostics were performed.

The customization method of fetal growth based on the previously noted 6 maternal and fetal factors calculates the term optimal weight at 40 weeks which is then extrapolated back to ultrasound EFW across gestation using the Hadlock reference, proportionately adjusting the percentiles (e.g., 10th, 50th, 90th) upward or downward based on the profile. Therefore, to check cross-sectional consistency of the variance, the heteroscedastic model was executed a second time using EFW for pairs of weeks, i.e., 21–22, 22–23, etc. instead of extrapolating. Pairs of weeks were chosen because there were insufficient observations at each individual week.

Both the heteroscedastic regression model with separately customizable mean and standard deviation and the quantile regression model that explicitly produced customized percentiles were then compared to the Gardosi model [29]. Note that under the normality assumption in the Gardosi and heteroscedastic models, the mean is equal to the median value. We computed the 5th, 10th, 50th, 90th and 95th percentiles for birthweight for deliveries at 37–41 weeks for a hypothetical mother whose customization factors were set to population average values in the NICHD Fetal Growth Studies–Singletons. The analysis was performed for each of the 3 models and the estimated percentiles were plotted for comparison. The equations to calculate the percentiles for the 3 models are presented in the Supplement. We also calculated the mean, median, SD, 10th, and 90th percentiles for the 3 models using EFW (instead of birthweight) at 38 and 39 weeks in the NICHD Fetal Growth Studies–Singletons.

We also compared the performance of the three customization models (Gardosi, heteroscedastic and quantile regression) and the Duryea birthweight reference in relation to SGA and LGA birthweight with neonatal morbidity and mortality [21]. Sensitivity, specificity, positive predictive values (PPV) and negative predictive values (NPV) were calculated for the association between each of the SGA and LGA classifications from the three customization models against the observed neonatal morbidity and mortality using multivariable logistic regression. Comparison of the performance of the customization models was first performed using the EFW at 38–39 weeks from the NICHD Fetal Growth Studies–Singletons. Analyses were then repeated using birthweight from the CSL study (because EFW was not available in the CSL). This step was for examining reproducibility and generalizability of the findings albeit using birthweight, since the CSL study included a much larger sample of deliveries on which out-of-sample prediction performance was tested. Moreover, the NICHD Fetal Growth Studies–Singletons targeted recruitment of low-risk pregnancies whose primary goal was developing a fetal growth standard, excluding pregnancies at higher risk for fetal growth abnormalities; the recruitment criterion for CSL did not have this restriction/limitation.

All analyses were completed with the use of SAS software (version 9·4, SAS Institute, Inc., Cary, NC) or R (version 3·5·2, available at http://www.R-project.org).

Results

Of the 2802 women recruited for the NICHD Fetal Growth Studies–Singletons, we excluded those who were deemed ineligible after enrollment, fetal anomalies, neonatal aneuploidy, deactivated (e.g., for pregnancy loss, moved, pregnancy termination, or lost to follow-up), delivered < 37 weeks, or had missing information, leaving 2288 for final analysis (S1 Fig). Study participants were racially/ethnically diverse with a mean maternal age of 28.2 (± 5.4) years; 46% were nulliparous, 56% had a BMI 18.5 to < 25 kg/m2, 26% had a BMI 25 to < 30 kg/m2 and 16% a BMI 30.0 or greater kg/m2 (Table 1).

Table 1. Participant and pregnancy characteristics in the NICHD Fetal Growth Studies–Singletons (N = 2,288).

Characteristic n (%) or mean ± SD
Maternal age (y) 28.2 (5.4)
Maternal height (cm) 162.8 (7.0)
Maternal weight (kg) 67.4 (14.9)
BMI (kg/m2)  
    < 18.5 12 (0.5%)
    18.5 to < 25 1290 (56.4%)
    25 to < 30 595 (26.0%)
    30 to <35 251 (11.0%)
    ≥ 35 140 (6.1%)
Parity  
    0 1062 (46.4%)
    1 791 (34.6%)
    2+ 435 (19.0%)
Race/ethnic group  
    Non-Hispanic white 643 (28.1%)
    Non-Hispanic black 607 (26.5%)
    Hispanic 665 (29.1%)
    Asian/Pacific Islander 373 (16.3%)
Smoking 10 (0.4%)
Gestational Diabetes 96 (4.2%)
Maternal hypertensive disease  
    No Hypertension 2147 (93.8%)
    Mild Gestational Hypertension 59 (2.6%)
    Severe Gestational Hypertension 4 (0.2%)
    Mild Preeclampsia 48 (2.1%)
    Severe Preeclampsia 13 (0.6%)
    Unspecified Hypertension 17 (0.7%)
Other Diseases  
    Asthma 5 (0.2%)
    Thyroid disease 4 (0.2%)
    Hematologic disorders 5 (0.2%)
Antepartum bleeding 620 (27.1%)
Abruption 9 (0.4%)
Gestational age at delivery (wk) 39.5 (1.1)
Infant birthweight (g) 3390.6 (438.5)
Infant sex  
    Male 1162 (50.8%)
    Female 1126 (49.2%)
Neonatal death 1 (0.0%)
Paternal height (cm)a 177.66 (8.50)
Paternal weight (kg) a 84.8 (16.2)

a n = 2040

Data are from the NICHD Fetal Growth Studies–Singleton.

Evaluation of customization assumptions

In order to evaluate the assumptions of normality and constant CV we examined the data as follows. The data were sorted by the mean estimated TOW based on the Gardosi model and divided into eight contiguous equal length intervals, where each interval represents cases with a specific value of TOW (the mean birth weight value in the interval). The number of observations in each interval were not equal with fewer observations for the extreme intervals. However, there were substantial observations in each for the mean, the standard deviation and the percentiles to be estimated accurately. For each interval, we computed the empirical percentiles of birthweight and the standard deviation as well as the mean predicted TOW from the Gardosi model. We also computed the percentiles using the normality and the constant CV assumption from the Gardosi model. The results are presented in Figs 1 and 2. Fig 1 shows the relationship between the empirical percentiles of birthweight and those estimated based on Gardosi assumptions for different values of mean birthweight. The empirical percentiles often differ from those obtained from the model. The 5th percentile was generally being over-estimated by the model while the 95th was generally underestimated. The difference was as big as 150gm. In Fig 2, the standard deviation of TOW for specific values of mean TOW are presented. If the Gardosi assumption of constant CV was satisfied the standard deviations would fall on the line with constant slope equal to the value of the CV. However, we observed considerable departure from the constant CV model.

Fig 1. Empirical percentiles (5th and 95th) of term optimal birthweight at different levels of mean birthweight are compared with the percentiles obtained from the Gardosi model which assumes normality and constant CV to compute the percentiles.

Fig 1

Data are from the NICHD Fetal Growth Studies–Singleton. The lines are from the models while the points are empirical observations.

Fig 2. Empirical and Gardosi model based standard deviation of birthweight at different levels of mean birthweight.

Fig 2

The constant coefficient variation assumption in Gardosi model would imply the empirical standard deviations would fall along a straight line (red line) with constant CV value as its slope. However, the empirical based fitted line (blue line) differs from the line based on the Gardosi assumption and the empirical points don’t show a linear pattern. Data are from the NICHD Fetal Growth Studies–Singleton. The sample size of each group is 5, 25, 85, 292, 668, 822, 350, and 41 for the point representing the grouped bins from smallest to largest predicted birthweight, respectively.

We further investigated the assumption of normality by checking the residuals from the model fits for the Gardosi and the heteroscedastic models. The quantile regression does not assume normality and hence it was not included in the investigation. The residuals did not show any glaring departure from normality (S2 Fig).

Creation and comparison of three customization models

Table 2 presents the results from the 3 models. As expected, the term optimal weight of 3510 g was similar for both Gardosi and heteroscedastic models since the mean would be the same as the median under the assumption of normality. However, in the quantile regression, the median term optimal weight was lower, 3487 g, challenging the assumption of normality.

Table 2. Coefficients for three customization models in the NICHD Fetal Growth Studies–Singletons (N = 2,288).

  Gardosi Model a Heteroscedastic Model Quantile Regression Model
Variable Estimate SE P Estimate SE P Estimate 10% Estimate 50% Estimate 90% SE 50% P 50%
Mean Model                      
Intercept (Term Optimal Weight) 3509.722 21.250 < .0001 3510.000 21.264 < .0001 3069.076 3486.616 4041.833 24.289 < .0001
Gestational age (from 280 d)                      
Linear term 14.944 1.818 < .0001 14.944 1.850 < .0001 13.366 17.147 8.282 2.269 < .0001
Quadratic term -0.282 0.191 0.1403 -0.293 0.184 0.1103 -0.389 -0.403 -0.269 0.206 0.0509
Cubic term 0.026 0.012 0.034 0.025 0.012 0.0379 0.027 0.008 0.042 0.016 0.6414
Sex                      
Male 67.048 7.911 < .0001 67.048 8.002 < .0001 55.752 66.499 71.076 9.517 < .0001
Female -67.048 7.911 < .0001 -67.048 8.002 < .0001 -55.752 -66.499 -71.076 9.517 < .0001
Maternal height (from 163 cm)                      
Linear term 5.864 1.903 0.0021 5.861 2.007 0.0035 9.412 5.306 -4.789 2.129 0.0127
Quadratic term 0.041 0.117 0.7252 0.034 0.114 0.7691 0.173 0.130 -0.081 0.112 0.2464
Cubic term -0.001 0.008 0.8934 0.000 0.009 0.986 -0.018 0.002 0.020 0.008 0.7861
Maternal prepregnancy weight (from 64 kg)                      
Linear term 7.720 1.140 < .0001 7.721 1.170 < .0001 4.751 7.395 13.533 1.348 < .0001
Quadratic term -0.114 0.063 0.0706 -0.119 0.065 0.0669 -0.086 -0.157 -0.203 0.075 0.0372
Cubic term 0.000 0.001 0.6579 0.000 0.001 0.7709 -0.001 0.001 -0.001 0.001 0.5762
Race                      
Non-Hispanic black -189.435 21.695 < .0001 -189.435 21.880 < .0001 -182.776 -193.922 -225.116 24.380 < .0001
Hispanic -54.454 22.150 0.014 -54.454 22.964 0.0177 -77.925 -65.586 -74.850 28.232 0.0203
Asian/Pacific Islander -49.903 26.053 0.0556 -49.903 25.876 0.0538 -9.154 -69.425 -79.243 36.557 0.0577
Parity                      
1 92.614 18.070 < .0001 92.614 18.394 < .0001 72.759 97.666 59.634 22.623 < .0001
2+ 101.536 22.391 < .0001 101.536 23.535 < .0001 117.866 102.512 45.780 28.195 0.0003
Variance Model b                      
Intercept       374.598 14.777 < .0001          
Gestational age (from 280 d)                      
Linear term       -0.004 0.007 0.604          
Quadratic term       0.000 0.001 0.8844          
Cubic term       0.000 0.000 0.9483          
Sex                      
Male       0.025 0.030 0.4035          
Female       -0.025 0.030 0.4035          
Maternal height (from 163 cm)                      
Linear term       -0.012 0.007 0.0922          
Quadratic term       0.000 0.000 0.3882          
Cubic term       0.000 0.000 0.1498          
Maternal prepregnancy weight (from 64 kg)                      
Linear term       0.015 0.004 < .0001          
Quadratic term       0.000 0.000 0.6577          
Cubic term       0.000 0.000 0.5303          
Race                      
Non-Hispanic black       -0.111 0.082 0.1783          
Hispanic       -0.011 0.082 0.8963          
Asian/Pacific Islander       -0.041 0.100 0.6829          
Parity                      
1       0.039 0.070 0.5723          
2+       0.040 0.083 0.6278          

Note: 0.000 is used for any value <0.001.

a All three models included the same customizing variables containing cubic and quadratic terms of deviation of gestational time at delivery from the optimal 280 days mark a priori per the Gardosi model [12]. In addition to the six proposed “physiological” variables (as designated by the Gardosi method) that influence fetal growth, models also included smoking, BMI (kg/m2), gestational diabetes, gestational hypertensive disease/preeclampsia, and antepartum bleeding. Analysis was centered on 280 days’ gestation, height 163 cm, prepregnancy weight 64 kg, nulliparous, and Non-Hispanic White race/ethnicity. However, only the coefficients for the six “physiologic” variables were included in an additive model to calculate the term optimal weight percentiles.

b Variance is only for the heteroscedastic model.

The beta-coefficients and standard errors for the mean characteristics in the heteroscedastic model and the Gardosi models were similar (Table 2). Interestingly, only the linear terms for maternal height and weight were statistically significant (in both models) but not the quadratic or cubic terms. However, we retained the quadratic and cubic terms in the model since they are included in the Gardosi model, and our main interest was to assess the variance terms. In the heteroscedastic model, only pre-pregnancy weight significantly affected the standard deviation (linear term β = 0.0145). Some of the other variables showed a potentially non-constant influence on the variability of TOW. Standard goodness-of-fit and model diagnostics indicated that overall, all 3 models appeared to fit well whereas the residuals did not show any appreciable departure.

Evaluation of model performance across gestation

The heteroscedastic model was executed again using EFW for pairs of weeks, i.e., 21–22, 22–23, etc. instead of birthweight to check the cross-sectional consistency of variance (i.e., whether the model assumptions hold at any unspecified point in gestation, not just at delivery with birthweight) (S2 Table). Though sporadic differences in variances were observed by maternal weight and height, no systematic dependence on any particular characteristic was found across gestation. These findings from the rolling weekly pair analysis indicate that there was no specific departure from the heteroscedastic customization model across gestation. Interestingly, however, the main effects of three of the six characteristics, maternal height, weight, and parity, in mean customization model for EFW were not consistent across gestational weeks. Maternal height was associated with increased EFW from around 28 to 30 weeks of gestation, and again around 33 weeks onward. Maternal weight also was associated with increased EFW from around 29 to 31 weeks and again around 33 weeks onward. Increasing parity was associated with increased EFW starting at the beginning of the third trimester around 28 weeks, although did not reach statistical significance until towards the end of pregnancy (not adjusted for multiple testing).

Evaluation of model performance across customization characteristics

Comparison of the 5th, 10th, 50th, 90th and 95th percentiles among the three models were performed for the six characteristics to evaluate model performance. Analyses comparing birthweight for deliveries at 37–41 weeks in the NICHD Fetal Growth Studies–Singletons are presented in Fig 3 for illustration. The 50th percentile was similar across all 3 models with the quantile regression percentile being only slightly lower than the other two. The percentiles for the Gardosi model were father apart than the other two models, meaning that there was a slightly lower birthweight for the 5th and 10th percentile cutpoints and slightly higher birthweight for the 90th and 95th percentile cutpoints than the heteroscedastic and quantile regression models which were more aligned. In the heteroscedastic and quantile regression models, EFW 10th and 90th percentiles were also closer to one another than the Gardosi model across a range of maternal weights: 57kg, 64kg and 75kg for the 25th, 50th, and 75th percentiles, respectively (Table 3). For example, EFW 10th percentile at 37–38 weeks for a woman with a pre-pregnancy weight of 57 kg was 99g larger with customized variance (2571g heteroscedastic) and 131 g larger for quantile regression (2603 g) vs. Gardosi (2472 g), while EFWs at the 90th percentile were 99 g and 26 g smaller, respectively.

Fig 3. Comparison of the three customization models for birthweight at term.

Fig 3

The 5th, 10th, 50th, 90th and 95th percentiles for the Gardosi, heteroscedastic and quantile regression models for birthweight for deliveries at 37–41 weeks. Data are from the NICHD Fetal Growth Studies–Singleton.

Table 3. Comparison of three different methods across different levels of maternal prepregnancy weight for birthweight at 37–42 weeks in the NICHD Fetal Growth Studies–Singletons (N = 2,288).

  25th percentile maternal weight 50th percentile maternal weight 75th percentile maternal weight
Prepregnancy weight–kg 56.7 63.5 74.8
Gardosi 90th Percentile–g 4017 4085 4170
Heteroscedastic 90th Percentile–g 3901 3984 4094
Quantile regression 90th Percentile–g 3932 4035 4164
Gardosi Term Optimal Weight–g 3447 3506 3579
Heteroscedastic Term Optimal Weight–g 3447 3506 3579
Quantile regression Term Optimal Weight–g 3424 3483 3549
Gardosi 10th Percentile–g 2878 2927 2988
Heteroscedastic 10th Percentile–g 2994 3028 3065
Quantile regression 10th Percentile–g 3030 3067 3109

Note: All calculations were performed in SAS with non-rounded numbers. Proc GLM was used for the Gardosi based models, Proc AUTOREG was used for the heteroscedastic models and Proc QUANTREG was used for the quantile regression model. The percentiles were calculated per the equations in S1 Table. For example, the 90th percentile from the Gardosi model was calculated as term optimal weight (TOW) = TOW + (1.28 * Sigma), where sigma = TOW*0.129, and where .129 is the coefficient of variation for the study population; the 90th percentile for the heteroscedastic model was calculated as TOW = TOW + (1.28*customized sigma), where the customized sigma was determined using the customized variance beta coefficients: 354.504 for the 25th maternal weight percentile, 373.2451 for the 50th maternal weight percentile, 402.0685 for the 75th maternal weight percentile. For example, for the 25th maternal weight percentile

epsi_het25 = 374.5975 *exp(0.5*(0.0145*(-7.301)-0.000103*(-7.301*-7.301)-0.0000028*(-7.301*-7.301*-7.301)

-0.0123*(0) -0.000357*(0)+0.0000472*(0)

-0.003582*(0) -0.000112*(0) -0.000003257*(0)

+ 0*(-0.1109)+ 0*(-0.0107)+ 0*(-0.0407)+ 0*(0.0394)+ 0*(0.0403)

+ 0.0236*(0)))

In both the Gardosi and Heteroscedastic, TOW was specific to each maternal weight percentile. For the quantile regression, the 10th and 90th percentiles were calculated directly from the model.

Assessment of the effect of paternal characteristics on birthweight

Paternal height and weight were also independently associated with birthweight (S3 Table). In general, for each cm increase in paternal height from the average 177.8 cm, there was an approximately 3 g increase in EFW (4 g using quantile regression), compared to the 5 g increase (4 g increase for quantile regression) in EFW for each cm increase in maternal height from the average 163 cm when both were included in the model. For each 1 kg increase in paternal weight from the 81.6 kg average, there was also a 3 g increase in EFW compared to the 7 g increase in EFW for each kg increase in maternal weight from the average of 64 kg.

Summary of actual and predicted birthweight for the NICHD Fetal Growth Studies-Singletons

To evaluate comparative model performance, we calculated the median, 10th, 90th percentiles for birthweight in the NICHD Fetal Growth Study. The empiric (observational) mean birthweight (37–41 weeks) was 3371 g which was similar to the estimated term optimal birthweight of 3374 g for the Gardosi model and 3375 g for the heteroscedastic model, indicating that these models performed well at estimating observed mean birthweight. The estimated term optimal birthweight from the quantile regression was 3350 g, which was 22 g lower than the observed birthweight and expected since the quantile regression is modeling the median of the distribution rather than the mean. The standard deviations of the predicted birthweights were narrower for the customization models (248 g for Gardosi, 246 g for the heteroscedastic, and 234 g for the quantile regression) compared to 447 g for the observed birthweight. This difference can be explained because the extremes of the observed birthweight distribution are more widely dispersed than those of the predicted distributions. Such a phenomenon is not unexpected. Since the customization models use measures of central tendency (i.e., mean/median), the predicted distributions of birthweights are well-aligned with the observed distribution at the center of the data. The discrepancy in the percentiles between the observed distributions and the predicted distributions are more pronounced toward the tail of the distribution, with the 10th and the 90th percentiles differing by two to three hundred grams.

Neonatal morbidity prediction across three customization models

Finally, we applied the models to birthweight data at 37–41 weeks in the CSL and compared classification of SGA and LGA in relation to neonatal morbidity and mortality in the CSL (Table 4). While the composite neonatal morbidity and mortality rates in relation to SGA were higher for the heteroscedastic and quantile regression models (10.3% and 10.0%, respectively) than the Gardosi model (7.2%), the prediction performance was similar among the 3 customization models as well as the Duryea population-based birthweight reference (c-statistic 0.52–0.54) [21]. The pattern was similar for LGA (c-statistic 0.53 for all). Findings were similar in the NICHD Fetal Growth Studies–Singletons analysis for EFW at 38–39 weeks (S4 Table).

Table 4. Comparison of model performance for the three different methods in detecting SGA and LGA with morbidity for birthweight at 37–42 weeks of gestation in the Consortium on Safe Labor study (N = 102,012).

Classification n Composite neonatal morbidity % PPV NPV Sensitivity Specificity Odds ratio (95% CI) c-statistic (95% CI)
LGA > 90th
Duryea 9,895 9.7 7.7 95.1 14.5 90.6 1.62 (1.50–1.75) 0.53 (0.52–0.53)
Gardosi 7,814 7.7 8.5 95.1 12.6 92.6 1.80 (1.65–1.96) 0.53 (0.52–0.53)
Heteroscedastic 10,497 10.3 7.7 95.1 15.3 90.0 1.63 (1.50–1.76) 0.53 (0.52–0.53)
Quantile 10,211 10.0 8.0 95.1 15.4 90.3 1.69 (1.56–1.83) 0.53 (0.52–0.53)
SGA < 10th
Duryea 9,385 9.2 6.5 96.3 15.2 91.04 1.82 (1.66–1.99) 0.54 (0.53–0.54)
Gardosi 7,294 7.2 7.2 96.3 13.2 93.09 2.05 (1.86–2.25) 0.53 (0.52–0.53)
Heteroscedastic 10,538 10.3 5.6 96.3 14.9 89.85 1.55 (1.41–1.69) 0.52 (0.52–0.52)
Quantile 10,201 10.0 5.9 96.3 15.0 90.20 1.63 (1.49–1.78 0.53 (0.52–0.53)

Note: In the Consortium on Safe Labor Study, birthweight was predicted by using models’ coefficients from the NICHD Fetal Growth Studies. Large- and small-for-gestational-age (LGA and SGA, respectively) were defined according to different models, then calculated the positive predictive value (PPV), negative predictive value (NPV), sensitivity, specificity, odds ratio and c-statistic using neonatal morbidity as the outcome. Neonatal morbidities were selected specifically for SGA or LGA based on increased risks associated with these and included: metabolic acidosis (pH <7.1 and base deficit >12mmol/L), NICU stay greater than three days, pneumonia, respiratory distress syndrome, persistent pulmonary hypertension, seizures, hyperbilirubinemia requiring exchange transfusion, intrapartum aspiration (meconium, amniotic fluid, blood), neonatal death, mechanical ventilation at term, necrotizing enterocolitis, hypoglycemia, hypoxic ischemic encephalopathy, periventricular leukomalacia (SGA only), sepsis based on blood culture (SGA only), bronchopulmonary dysplasia/chronic lung disease (SGA only), retinopathy of prematurity (SGA only), and birth injury (LGA only) [2226].

Discussion

We performed an in-depth examination of the statistical assumptions of the Gardosi customization method [4]. Our investigation indicates that the standard deviation varies differently than the mean birthweight across gestation for the six customization characteristics. These findings question the constant coefficient of variation assumption of the Gardosi customization model that the standard deviation, and therefore the customized percentiles, is proportional to the mean birthweight. Therefore, we created a model to simultaneously estimate both customized mean and standard deviation with heteroscedastic regression. Also, since our findings questioned the assumption that the data were normally distributed, we further investigated direct customization using a quantile regression model that does not assume normal distribution. While 50th percentile EFW was similar across models, 10th and 90th percentiles for the Gardosi model were father apart, resulting in lower birthweight for 10th percentile and higher for 90th percentile cutpoints, than other two models. Composite neonatal morbidity and mortality rates in relation to birthweight < 10th percentile was higher for the heteroscedastic and quantile regression models (10.3% and 10.0%, respectively) than the Gardosi model (7.2%), although prediction performance was similar among all three (c-statistic 0.52–0.53). Thus, while there was some departure from the assumptions of the Gardosi model, it still performed well in comparison to a more flexible heteroscedastic model. While quantile regression resolves the issue about assumption of normality, its similar performance in estimating the percentiles indicates that other two models may generally be robust with respect to the assumption of normality, at least for the study population considered, since the effect of non-normality did not have an appreciable impact on model performance. In summary, the heteroscedastic model is equally straightforward to implement as the Gardosi model and has the advantage of being able to capture unstable variance in the customization characteristics if needed.

The quantile regression model seems to be a natural choice for modeling quantiles when standard assumptions of normal distribution models are suspect. Quantile regression was used to create the WHO fetal growth charts and also for a customized fetal growth reference in an African-American population [30, 31]. However, the price of the greater flexibility of the quantile regression is that it generally requires a greater sample size to yield accuracy as comparable to the linear regression models [17]. In the study by Kabiri et al., a customized fetal growth reference based on quantile regression did not improve prediction of perinatal morbidity compared with ultrasound references [30]. While in the present cohort the model also did not show significant improvement in terms of birthweight prediction, it is expected that as more data from controlled studies become available, the merits of flexible models compared to linear regression-based models could be better evaluated in the context of birthweight customization.

Our investigation into the statistical assumptions of customization methods of proportional standard deviation across birthweight values is novel. In addition, the effect of the covariates on fetal growth across gestation had also been assumed to be fixed, but we found the effect of pre-pregnancy weight on EFW was both nonconstant and non-linear, and in the heteroscedastic model, maternal pre-pregnancy weight significantly affected the variance. Maternal height and parity were also associated with increased EFW starting at the beginning of the third trimester, with little influence in the first and second trimesters. Some of the other customization variables showed some non-constant influence on the distribution of EFW, although these findings were not statistically significant which could have been due to limited power. Also, the quadratic or cubic terms for maternal height and weight were not statistically significant in either the Gardosi or heteroscedastic model, indicating that a linear term may be sufficient. Removal of maternal weight from the customization model has previously been found to identify a greater proportion of LGA neonates with deliveries complicated by shoulder dystocia, NICU admission and neonatal respiratory problems that were not identified by a population based definition of LGA, although that analysis used the outcome of birthweight [32]. These findings indicate that the characteristics (i.e. maternal weight) and terms in the Gardosi customization model (i.e. quadratic and cubic) that are currently included may be unnecessary. In our analysis of EFW at 38–39 weeks, customization with the heteroscedastic model identified a slightly higher proportion of SGA neonates with morbidity (8.9%) compared to the Gardosi method (5.7%), with a similar pattern for LGA and SGA neonates < 5th percentiles. Perhaps the ability of the heteroscedastic model to allow for unstable variance in the customization characteristics yielded a slight incremental improvement. Therefore, the heteroscedastic customization method has potential to identify more fetuses at risk of growth restriction and macrosomia, with associated improvement in targeting antenatal surveillance and obstetric intervention to reduce neonatal morbidity and stillbirths.

Paternal factors have not traditionally been included in customization charts. We found that increasing paternal height and weight had a positive, independent influence on fetal growth, although maternal height and weight had a stronger effect. These findings are similar to findings from the Generation R cohort of EFW in the Netherlands [33] and fetal biometric measurements in an Italian cohort [34] although another study from the UK also found maternal weight to have a stronger influence on birthweight, while maternal and paternal height had similar contributions [35]. The fact that maternal factors have a stronger influence on anthropometrics during fetal life compared to paternal factors has been hypothesized to be due to maternal preservation in conditions of constraint [36].

While the six customization characteristics (gestational age, maternal pre-pregnancy weight, height, race, parity, infant sex) are known to influence fetal growth, it is unclear whether the changes in fetal growth in relation to these characteristics are a normal physiologic adaptation or associated with increased risk for perinatal morbidity and mortality. Since shorter and lighter women would be expected to have smaller neonates than taller and heavier women, taking maternal height and weight into account should help identify fetuses that are more likely to be constitutionally small or overgrown instead of being erroneously labeled as not aligned with their growth potential [37]. While country (as a proxy for local ethnic mix) has been found to be the principal factor in predicting adverse outcomes in infants compared with customizing for additional individual characteristics, there is increased recognition that customizing for race/ethnicity might have unintended clinical consequences [38, 39]. Birthweight is also known to increase with increasing parity until parity 4, with the largest increase between parity 0 and 1 (68 g on average) [40]. Male neonates weigh larger than females, an average 141 g larger at 40 weeks of gestation [21]. However, the influence of maternal short stature and nulliparity on perinatal mortality has been found to be mediated in part through SGA indicating that smaller EFW associated with maternal constraint is both physiological and pathological [41]. Finally, other factors can influence fetal growth, such as genetic and external factors, including altitude, diet and lifestyle, and other environmental conditions beyond the six factors included in the customization profile that are often routinely and easily obtained during the antenatal period [29, 4247].

Our study only found incremental improvements in detection of rates of neonatal morbidity and mortality at term with SGA and LGA defined by all three customization models compared to population based birthweight reference, with no difference in predictive ability (i.e., similar c-statistics across the models) which may have been due to smaller numbers of adverse outcomes in a healthier population initially recruited for the primary study goals to create a fetal growth standard [18]. However, the ability to test the customized methods in the CSL, a large pregnancy cohort, with consistent results as our smaller ultrasound study strengthens our findings. A major strength of our study was the longitudinal collection of ultrasound fetal measurements which allowed us to evaluate the effect of the six customization characteristics across gestation, and also the ability to explore not only birthweight but EFW which is arguably more important clinically when considering obstetrical interventions such as antenatal monitoring and earlier delivery to prevent stillbirth and birth related complications.

The concept of considering maternal and fetal characteristics is appealing as a personalized medicine approach, although there is controversy on whether customization for maternal and fetal factors improves clinically useful detection of SGA and LGA [6, 7]. Yet, the incremental improvement depends on several factors and the obstetric implications of customization have been understudied [8]. All three of the customization methods and the population-based birthweight reference had poor discrimination ability to predict neonatal morbidity and mortality indicating that we need to move beyond using a percentile cut-point to identify fetuses at risk even though this remains standard practice. Similarly, use of percentile cut-points to identify SGA and LGA is also ingrained in standard care, and customization is used in clinical practice [9]. We found that a customizing heteroscedastic model that allows for unstable variance in the customization characteristics may represent an incremental improvement over current customization methods in current use. Future work may consider additional maternal, fetal, and paternal factors and identify other factors related to neonatal morbidity and mortality. Randomized clinical trials are ultimately needed to compare whether and which customized chart is associated with reductions in short and long-term neonatal morbidity.

Supporting information

S1 Fig. Flowchart for study participants included in analysis.

From the NICHD Fetal Growth Studies–Singletons.

(DOCX)

S2 Fig. Residuals from the model fits.

The residuals from the model fits for the Gardosi and the heteroscedastic models did not show any glaring departure from normality. The quantile regression does not assume normality and hence it was not included.

(EPS)

S1 Table. Equations to calculate the percentiles for the Gardosi, heteroscedastic and quantile regression models.

(DOCX)

S2 Table. Model characteristics for Pairs of weeks.

(XLSX)

S3 Table. Customization coefficients for customized three models with the addition of paternal height and weight.

(DOCX)

S4 Table. Comparison of model performance for the three different methods in detecting SGA and LGA with morbidity in the NICHD Fetal Growth Studies–Singletons (N = 2,288).

(DOCX)

Acknowledgments

Institutions in the NICHD Fetal Growth Studies–Singletons include, in alphabetical order:

Christiana Care Health Systems, Newark, DE; Columbia University Medical Center, New York, NY; Fountain Valley Regional Medical Center, Fountain Valley, CA; Long Beach Memorial Medical Center, Long Beach, CA; Medical University of South Carolina, Charleston, SC; New York Hospital Queens, Flushing, NY; Northwestern University Feinburg School of Medicine, Chicago, IL; Saint Peters University Hospital, New Brunswick, NJ; The Emmes Corporation, Rockville, MD (Data coordinating center); Tufts University, Boston, MA; University of Alabama, Birmingham, AL; University of California, Irvine, Medical Center, Orange, CA; Women and Infants Hospital of Rhode Island, Providence, RI.

Institutions involved in the Consortium on Safe Labor study include, in alphabetical order: Baystate Medical Center, Springfield, MA; Cedars-Sinai Medical Center Burnes Allen Research Center, Los Angeles, CA; Christiana Care Health System, Newark, DE; Georgetown University Hospital, MedStar Health, Washington, DC; Indiana University Clarian Health, Indianapolis, IN; Intermountain Healthcare and the University of Utah, Salt Lake City, Utah; Maimonides Medical Center, Brooklyn, NY; MetroHealth Medical Center, Cleveland, OH.; Summa Health System, Akron City Hospital, Akron, OH; The EMMES Corporation, Rockville MD (Data Coordinating Center); University of Illinois at Chicago, Chicago, IL; University of Miami, Miami, FL; and University of Texas Health Science Center at Houston, Houston, Texas.

Data Availability

Data and accompanying files for the NICHD Fetal Growth Study are available through NICHD BRADS, https://brads.nichd.nih.gov/. The Consortium on Safe Labor study data are publicly available through the NICHD Data and Specimen Hub (DASH) https://dash.nichd.nih.gov/.

Funding Statement

This research was supported, in part, by the Division of Population Health Research, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health; and, in part, with Federal funds for the NICHD Fetal Growth Studies – Singletons (Contract Numbers: HHSN275200800013C; HHSN275200800002I; HHSN27500006; HHSN275200800003IC; HHSN275200800014C; HHSN275200800012C; HHSN275200800028C; HHSN275201000009C); and in part, with Federal funds for the Consortium on Safe Labor (Contract Number HHSN267200603425C). KLG has contributed to this work as part of her official duties as an employee of the United States Federal Government. Intramural investigators designed the study that was implemented by clinical site investigators. For the present analysis, the funder had no role in study design, data analysis, or preparation of the manuscript. All manuscripts undergo clearance before submission for publishing.

References

  • 1.ACOG Practice Bulletin No. 204: Fetal Growth Restriction. Obstet Gynecol. 2019;133(2):e97–e109. Epub 2019/01/27. doi: 10.1097/AOG.0000000000003070 . [DOI] [PubMed] [Google Scholar]
  • 2.Battaglia FC, Lubchenco LO. A practical classification of newborn infants by weight and gestational age. The Journal of pediatrics. 1967;71(2):159–63. Epub 1967/08/01. doi: 10.1016/s0022-3476(67)80066-0 . [DOI] [PubMed] [Google Scholar]
  • 3.Gardosi J, Chang A, Kalyan B, Sahota D, Symonds EM. Customised antenatal growth charts. Lancet. 1992;339(8788):283–7. Epub 1992/02/01. doi: 10.1016/0140-6736(92)91342-6 . [DOI] [PubMed] [Google Scholar]
  • 4.Gardosi J, Mongelli M, Wilcox M, Chang A. An adjustable fetal weight standard. Ultrasound Obstet Gynecol. 1995;6(3):168–74. Epub 1995/09/01. doi: 10.1046/j.1469-0705.1995.06030168.x . [DOI] [PubMed] [Google Scholar]
  • 5.Hadlock FP, Harrist RB, Martinez-Poyer J. In utero analysis of fetal growth: a sonographic weight standard. Radiology. 1991;181(1):129–33. Epub 1991/10/01. doi: 10.1148/radiology.181.1.1887021 . [DOI] [PubMed] [Google Scholar]
  • 6.Hutcheon JA, Zhang X, Platt RW, Cnattingius S, Kramer MS. The case against customised birthweight standards. Paediatric and perinatal epidemiology. 2011;25(1):11–6. Epub 2010/12/08. doi: 10.1111/j.1365-3016.2010.01155.x . [DOI] [PubMed] [Google Scholar]
  • 7.Carberry AE, Raynes-Greenow CH, Turner RM, Jeffery HE. Customized versus population-based birth weight charts for the detection of neonatal growth and perinatal morbidity in a cross-sectional study of term neonates. Am J Epidemiol. 2013;178(8):1301–8. Epub 2013/08/24. doi: 10.1093/aje/kwt176 . [DOI] [PubMed] [Google Scholar]
  • 8.Zhang J, Sun K. Invited commentary: the incremental value of customization in defining abnormal fetal growth status. Am J Epidemiol. 2013;178(8):1309–12. Epub 2013/08/24. doi: 10.1093/aje/kwt174 . [DOI] [PubMed] [Google Scholar]
  • 9.McCowan LM, Figueras F, Anderson NH. Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy. Am J Obstet Gynecol. 2018;218(2S):S855–S68. Epub 2018/02/10. doi: 10.1016/j.ajog.2017.12.004 . [DOI] [PubMed] [Google Scholar]
  • 10.Vieira MC, Relph S, Muruet-Gutierrez W, Elstad M, Coker B, Moitt N, et al. Evaluation of the Growth Assessment Protocol (GAP) for antenatal detection of small for gestational age: The DESiGN cluster randomised trial. PLoS medicine. 2022;19(6):e1004004. Epub 20220621. doi: 10.1371/journal.pmed.1004004 ; PubMed Central PMCID: PMC9212153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Duhig K, Myers J. Detecting fetal growth restriction with customised assessment: Is the jury still out? PLoS medicine. 2022;19(6):e1004028. Epub 20220621. doi: 10.1371/journal.pmed.1004028 ; PubMed Central PMCID: PMC9212128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Gardosi J, Francis A. A customized standard to assess fetal growth in a US population. Am J Obstet Gynecol. 2009;201(1):25 e1-7. doi: 10.1016/j.ajog.2009.04.035 . [DOI] [PubMed] [Google Scholar]
  • 13.Buck Louis GM, Grewal J, Albert PS, Sciscione A, Wing DA, Grobman WA, et al. Racial/ethnic standards for fetal growth: the NICHD Fetal Growth Studies. Am J Obstet Gynecol. 2015;213(4):449 e1- e41. Epub 2015/09/28. doi: 10.1016/j.ajog.2015.08.032 ; PubMed Central PMCID: PMC4584427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Buck Louis GM, Grewal J. Clarification of estimating fetal weight between 10–14 weeks gestation, NICHD fetal growth studies. Am J Obstet Gynecol. 2017;217(1):96–101. Epub 2017/04/09. doi: 10.1016/j.ajog.2017.03.030 . [DOI] [PubMed] [Google Scholar]
  • 15.Grantz KL, Kim S, Grobman WA, Newman R, Owen J, Skupski D, et al. Fetal Growth Velocity: the NICHD Fetal Growth Studies. Am J Obstet Gynecol. 2018. Epub 2018/05/29. doi: 10.1016/j.ajog.2018.05.016 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Welsh AH, Carroll RJ, Ruppert D. Fitting Heteroscedastic Regression-Models. J Am Stat Assoc. 1994;89(425):100–16. doi: 10.2307/2291205 WOS:A1994MY54600011. [DOI] [Google Scholar]
  • 17.Koenker R. Quantile Regression: Cambridge University Press; 2005. [Google Scholar]
  • 18.Grewal J, Grantz KL, Zhang C, Sciscione A, Wing DA, Grobman WA, et al. Cohort Profile: NICHD Fetal Growth Studies-Singletons and Twins. Int J Epidemiol. 2018;47(1):25–l. Epub 2017/10/13. doi: 10.1093/ije/dyx161 ; PubMed Central PMCID: PMC5837516. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Zhang C, Hediger ML, Albert PS, Grewal J, Sciscione A, Grobman WA, et al. Association of Maternal Obesity With Longitudinal Ultrasonographic Measures of Fetal Growth: Findings From the NICHD Fetal Growth Studies-Singletons. JAMA Pediatr. 2018;172(1):24–31. Epub 2017/11/14. doi: 10.1001/jamapediatrics.2017.3785 ; PubMed Central PMCID: PMC5808867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Hadlock FP, Harrist RB, Sharman RS, Deter RL, Park SK. Estimation of fetal weight with the use of head, body, and femur measurements—a prospective study. Am J Obstet Gynecol. 1985;151(3):333–7. Epub 1985/02/01. doi: 10.1016/0002-9378(85)90298-4 . [DOI] [PubMed] [Google Scholar]
  • 21.Duryea EL, Hawkins JS, McIntire DD, Casey BM, Leveno KJ. A revised birth weight reference for the United States. Obstet Gynecol. 2014;124(1):16–22. Epub 2014/06/06. doi: 10.1097/AOG.0000000000000345 . [DOI] [PubMed] [Google Scholar]
  • 22.Longo S, Bollani L, Decembrino L, Di Comite A, Angelini M, Stronati M. Short-term and long-term sequelae in intrauterine growth retardation (IUGR). The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2013;26(3):222–5. Epub 2012/10/04. doi: 10.3109/14767058.2012.715006 . [DOI] [PubMed] [Google Scholar]
  • 23.Rosenberg A. The IUGR newborn. Seminars in perinatology. 2008;32(3):219–24. Epub 2008/05/17. doi: 10.1053/j.semperi.2007.11.003 . [DOI] [PubMed] [Google Scholar]
  • 24.Giapros V, Drougia A, Krallis N, Theocharis P, Andronikou S. Morbidity and mortality patterns in small-for-gestational age infants born preterm. The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2012;25(2):153–7. Epub 2011/04/06. doi: 10.3109/14767058.2011.565837 . [DOI] [PubMed] [Google Scholar]
  • 25.McIntire DD, Bloom SL, Casey BM, Leveno KJ. Birth weight in relation to morbidity and mortality among newborn infants. The New England journal of medicine. 1999;340(16):1234–8. Epub 1999/04/22. doi: 10.1056/NEJM199904223401603 . [DOI] [PubMed] [Google Scholar]
  • 26.King JR, Korst LM, Miller DA, Ouzounian JG. Increased composite maternal and neonatal morbidity associated with ultrasonographically suspected fetal macrosomia. The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2012;25(10):1953–9. Epub 2012/03/24. doi: 10.3109/14767058.2012.674990 . [DOI] [PubMed] [Google Scholar]
  • 27.Zhang J, Troendle J, Reddy UM, Laughon SK, Branch DW, Burkman R, et al. Contemporary cesarean delivery practice in the United States. American journal of obstetrics and gynecology. 2010;203(4):326 e1- e10. doi: 10.1016/j.ajog.2010.06.058 ; PubMed Central PMCID: PMC2947574. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Mannisto T, Mendola P, Reddy U, Laughon SK. Neonatal outcomes and birth weight in pregnancies complicated by maternal thyroid disease. Am J Epidemiol. 2013;178(5):731–40. Epub 2013/05/15. doi: 10.1093/aje/kwt031 ; PubMed Central PMCID: PMC3755642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Gardosi J. Customized fetal growth standards: rationale and clinical application. Seminars in perinatology. 2004;28(1):33–40. Epub 2004/04/03. doi: 10.1053/j.semperi.2003.12.002 . [DOI] [PubMed] [Google Scholar]
  • 30.Kabiri D, Romero R, Gudicha DW, Hernandez-Andrade E, Pacora P, Benshalom-Tirosh N, et al. Prediction of adverse perinatal outcome by fetal biometry: comparison of customized and population-based standards. Ultrasound Obstet Gynecol. 2020;55(2):177–88. doi: 10.1002/uog.20299 ; PubMed Central PMCID: PMC6810752. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Kiserud T, Piaggio G, Carroli G, Widmer M, Carvalho J, Neerup Jensen L, et al. The World Health Organization Fetal Growth Charts: A Multinational Longitudinal Study of Ultrasound Biometric Measurements and Estimated Fetal Weight. PLoS medicine. 2017;14(1):e1002220. Epub 2017/01/25. doi: 10.1371/journal.pmed.1002220 ; PubMed Central PMCID: PMC5261648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Sjaarda LA, Albert PS, Mumford SL, Hinkle SN, Mendola P, Laughon SK. Customized large-for-gestational-age birthweight at term and the association with adverse perinatal outcomes. Am J Obstet Gynecol. 2014;210(1):63 e1- e11. Epub 2013/09/17. doi: 10.1016/j.ajog.2013.09.006 ; PubMed Central PMCID: PMC3872267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Durmus B, Arends LR, Ay L, Hokken-Koelega AC, Raat H, Hofman A, et al. Parental anthropometrics, early growth and the risk of overweight in pre-school children: the Generation R Study. Pediatr Obes. 2013;8(5):339–50. Epub 2012/12/15. doi: 10.1111/j.2047-6310.2012.00114.x . [DOI] [PubMed] [Google Scholar]
  • 34.Ghi T, Cariello L, Rizzo L, Ferrazzi E, Periti E, Prefumo F, et al. Customized Fetal Growth Charts for Parents’ Characteristics, Race, and Parity by Quantile Regression Analysis: A Cross-sectional Multicenter Italian Study. J Ultrasound Med. 2016;35(1):83–92. Epub 20151207. doi: 10.7863/ultra.15.03003 . [DOI] [PubMed] [Google Scholar]
  • 35.Griffiths LJ, Dezateux C, Cole TJ. Differential parental weight and height contributions to offspring birthweight and weight gain in infancy. Int J Epidemiol. 2007;36(1):104–7. Epub 2006/09/21. doi: 10.1093/ije/dyl210 . [DOI] [PubMed] [Google Scholar]
  • 36.Skaren L, Davies B, Bjornerem A. The effect of maternal and paternal height and weight on antenatal, perinatal and postnatal morphology in sex-stratified analyses. Acta Obstet Gynecol Scand. 2020;99(1):127–36. Epub 2019/09/11. doi: 10.1111/aogs.13724 . [DOI] [PubMed] [Google Scholar]
  • 37.Mayer C, Joseph KS. Fetal growth: a review of terms, concepts and issues relevant to obstetrics. Ultrasound Obstet Gynecol. 2013;41(2):136–45. Epub 2012/06/01. doi: 10.1002/uog.11204 . [DOI] [PubMed] [Google Scholar]
  • 38.Mikolajczyk RT, Zhang J, Betran AP, Souza JP, Mori R, Gulmezoglu AM, et al. A global reference for fetal-weight and birthweight percentiles. Lancet. 2011;377(9780):1855–61. Epub 2011/05/31. doi: 10.1016/S0140-6736(11)60364-4 . [DOI] [PubMed] [Google Scholar]
  • 39.Vyas DA, Eisenstein LG, Jones DS. Hidden in Plain Sight—Reconsidering the Use of Race Correction in Clinical Algorithms. The New England journal of medicine. 2020;383(9):874–82. Epub 2020/08/28. doi: 10.1056/NEJMms2004740 . [DOI] [PubMed] [Google Scholar]
  • 40.Hinkle SN, Albert PS, Mendola P, Sjaarda LA, Yeung E, Boghossian NS, et al. The association between parity and birthweight in a longitudinal consecutive pregnancy cohort. Paediatric and perinatal epidemiology. 2014;28(2):106–15. Epub 2013/12/11. doi: 10.1111/ppe.12099 ; PubMed Central PMCID: PMC3922415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Zhang X, Mumford SL, Cnattingius S, Schisterman EF, Kramer MS. Reduced birthweight in short or primiparous mothers: physiological or pathological? BJOG. 2010;117(10):1248–54. Epub 2010/07/14. doi: 10.1111/j.1471-0528.2010.02642.x ; PubMed Central PMCID: PMC3071625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Kramer MS. Determinants of low birth weight: methodological assessment and meta-analysis. Bulletin of the World Health Organization. 1987;65(5):663–737. Epub 1987/01/01. ; PubMed Central PMCID: PMC2491072. [PMC free article] [PubMed] [Google Scholar]
  • 43.Gluckman PD, Hanson MA, Buklijas T. A conceptual framework for the developmental origins of health and disease. Journal of developmental origins of health and disease. 2010;1(1):6–18. Epub 2010/02/01. doi: 10.1017/S2040174409990171 . [DOI] [PubMed] [Google Scholar]
  • 44.Frisancho AR. Developmental functional adaptation to high altitude: review. Am J Hum Biol. 2013;25(2):151–68. Epub 2013/09/26. doi: 10.1002/ajhb.22367 . [DOI] [PubMed] [Google Scholar]
  • 45.Tekola-Ayele F, Workalemahu T, Amare AT. High burden of birthweight-lowering genetic variants in Africans and Asians. BMC Med. 2018;16(1):70. Epub 2018/05/25. doi: 10.1186/s12916-018-1061-3 ; PubMed Central PMCID: PMC5967042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Tekola-Ayele F, Zhang C, Wu J, Grantz KL, Rahman ML, Shrestha D, et al. Trans-ethnic meta-analysis of genome-wide association studies identifies maternal ITPR1 as a novel locus influencing fetal growth during sensitive periods in pregnancy. PLoS Genet. 2020;16(5):e1008747. Epub 2020/05/15. doi: 10.1371/journal.pgen.1008747 ; PubMed Central PMCID: PMC7252673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Tekola-Ayele F, Ouidir M, Shrestha D, Workalemahu T, Rahman ML, Mendola P, et al. Admixture mapping identifies African and Amerindigenous local ancestry loci associated with fetal growth. Hum Genet. 2021. Epub 2021/02/17. doi: 10.1007/s00439-021-02265-4 . [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Quetzal A Class

Transfer Alert

This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.

23 Nov 2022

PONE-D-22-23564A new method for customized fetal growth reference percentilesPLOS ONE

Dear Dr. Grantz,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jan 07 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Quetzal A. Class, PhD

Academic Editor

PLOS ONE

Journal Requirements

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for including your ethics statement:  "IRB approval was obtained at all institutions as well as the NIH #09-CH-N152 on December 2009. Participants gave written informed consent prior to collection of data."

For studies reporting research involving human participants, PLOS ONE requires authors to confirm that this specific study was reviewed and approved by an institutional review board (ethics committee) before the study began. Please provide the specific name of the ethics committee/IRB that approved your study, or explain why you did not seek approval in this case.

Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the “Ethics Statement” field of the submission form (via “Edit Submission”).

For additional information about PLOS ONE ethical requirements for human subjects research, please refer to http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research.

3. Thank you for stating the following financial disclosure: 

This research was supported, in part, by the Division of Population Health Research, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health; and, in part, with Federal funds for the NICHD Fetal Growth Studies – Singletons (Contract Numbers:  HHSN275200800013C; HHSN275200800002I; HHSN27500006; HHSN275200800003IC; HHSN275200800014C; HHSN275200800012C; HHSN275200800028C; HHSN275201000009C); and in part, with Federal funds for the Consortium on Safe Labor (Contract Number HHSN267200603425C). KLG has contributed to this work as part of her official duties as an employee of the United States Federal Government.

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." 

If this statement is not correct you must amend it as needed. 

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

4. Thank you for stating the following in the Acknowledgments Section of your manuscript: 

This research was supported, in part, by the Division of Population Health Research, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health; and, in part, with Federal funds for the NICHD Fetal Growth Studies – Singletons (Contract Numbers:  HHSN275200800013C; HHSN275200800002I; HHSN27500006; HHSN275200800003IC; HHSN275200800014C; HHSN275200800012C; HHSN275200800028C; HHSN275201000009C); and in part, with Federal funds for the Consortium on Safe Labor (Contract Number HHSN267200603425C). KLG has contributed to this work as part of her official duties as an employee of the United States Federal Government.

However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. 

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: 

This research was supported, in part, by the Division of Population Health Research, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health; and, in part, with Federal funds for the NICHD Fetal Growth Studies – Singletons (Contract Numbers:  HHSN275200800013C; HHSN275200800002I; HHSN27500006; HHSN275200800003IC; HHSN275200800014C; HHSN275200800012C; HHSN275200800028C; HHSN275201000009C); and in part, with Federal funds for the Consortium on Safe Labor (Contract Number HHSN267200603425C). KLG has contributed to this work as part of her official duties as an employee of the United States Federal Government.

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

5. We noted in your submission details that a portion of your manuscript may have been presented or published elsewhere. Please clarify whether this conference proceeding or publication was peer-reviewed and formally published. If this work was previously peer-reviewed and published, in the cover letter please provide the reason that this work does not constitute dual publication and should be included in the current manuscript.

6. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. 

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

7. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

8. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

9. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well. 

10. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 

Additional Editor Comments:

Dear Author,

Thank you for your contribution. We continue to assert that your work is important, though the reviewers and I believe that it would be stronger with some further thoughts and considerations as well as some qualification in your claims. Please see both reviewers' comments and address.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: In this study Authors constructed a new model for predicting fetal growth, The subject is of interest, the ms well written so I would like to congratulate with Authors for their effort

My comments are

1)since many of the reader are not familirar with heteroscedastic model I suggest to add an explanation of the rationale of using this approach and how it was constructed

2)of interest it should be the % variation at each gestational age in the comparison of the 3 models and if differences are significant

3) i will consider in the reference list and in the discussion the paper of Ghi et al JUM 2016 that similarly also used father characteristics in the construction of the customized mode

Reviewer #2: The authors use longitudinal fetal weight measurements they obtained in the NICHD Fetal Growth Studies to assess some of the assumptions of the Gardosi’s customized chart which assumes that i) standard deviation is a fixed proportion of the mean, and that ii) the effect of maternal characteristics is proportional throughout gestation and affects all percentiles of the distribution. Specifically, the authors evaluated the normality and constant coefficient of variation (CV) assumptions and propose the hetroscedastic and quantile regressions based percentiles as an alternative.

Major:

1) Although the attention to the non-normality of the fetal growth data is warranted, the WHO and PRB/NICHD standards already proposed the use of quantile regression. Moreover, the PRB/NICHD standard questioned the proportionality of the effects of maternal characteristics and showed differential effects on specific percentiles. The paper should put these results in perspective and perhaps somehow tone down claims of novelty.

2) Comparison of customized and non-customized standards were also evaluated for prediction of adverse outcomes and the authors miss to acknowledge and discuss previous work (https://pubmed.ncbi.nlm.nih.gov/31006913/).

3) Studying the behavior of the mean and SD only answers questions about the constant CV, but not about the normality. This should better emphasized the paper.

4. For the assessment of normality, the authors compare the Gardosi percentile with the percentiles generated empirically (for each sub-interval). This does not really answer the question, as the difference between the two values may also be the result of violation of the constant CV (proportionality) assumption. Other contributing factors could be the different datasets involved (Gardosi uses all the avalble data set; empirical uses a dataset in a given sub-interval).

5. In Fig 1, we the black line (and dots) for Gardosi model are missing but shown in the legend.

6. The authors noted that “In Fig 2…. If the Gardosi assumption of constant CV was satisfied the standard deviation would fall on the line with constant slope.” This can be true provided that data points in each interval are sufficiently large. It’s important that the authors also give number of data points in each interval.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Giuseppe Rizzo

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Mar 16;18(3):e0282791. doi: 10.1371/journal.pone.0282791.r002

Author response to Decision Letter 0


23 Jan 2023

Note- response to the reviewer comments were also provided in a Word document in the Cover Letter.

Editor Comments:

Dear Author,

Thank you for your contribution. We continue to assert that your work is important, though the reviewers and I believe that it would be stronger with some further thoughts and considerations as well as some qualification in your claims. Please see both reviewers' comments and address.

[Note: HTML markup is below. Please do not edit.]

Response: Thank you for the opportunity to revise the manuscript. We have addressed the reviewers comments as outlined below.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

________________________________________

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: Yes

________________________________________

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS ONE data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

________________________________________

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

________________________________________

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: In this study Authors constructed a new model for predicting fetal growth, The subject is of interest, the ms well written so I would like to congratulate with Authors for their effort

My comments are

1) since many of the reader are not familirar with heteroscedastic model I suggest to add an explanation of the rationale of using this approach and how it was constructed

Response: The Gardosi method constructs the percentile cutpoints to define SGA and LGA, namely, 10th and 90th, in a specific way. The method is based on the assumption that the coefficient of variation (CV) is constant. Our first objective was to investigate this assumption. For the second objective, the advantage of creating a new method for customization using a heteroscedastic model is that it directly calculates the CV based on the empiric data without making such assumption. Therefore, the heteroscedastic model allows for more flexibility. We have clarified this description in the Introduction (new text underlined) (Pages 4-5):

“Second, we developed an expanded, alternative TOW customization method for estimating we created a new customization method that has more flexibility in calculating customized percentiles using a heteroscedastic regression that customizes both customized mean TOW (and hence EFW by extrapolation) and customized standard deviation, leading to customized percentiles, using a heteroscedastic regression.[16] To be precise, the heteroscedastic model customizes a transformed value of the standard deviation but because that makes the standard deviation depend on the customizing factors, hereafter we refer to it as a model for customizing the standard deviation.”

2) of interest it should be the % variation at each gestational age in the comparison of the 3 models and if differences are significant

Response: Thank you for this suggestion. We revised Figure 3 to add confidence bands for the 10th and 90th percentiles for each week. (new Fig 3) We also provide the percentiles by week to present the absolute differences and calculated the relative differences in the Table below:

GA Range of 90th and 10th in Gardosi Range of 90th and 10th in Hetero Range of 90th and 10th in Quantile Relative difference between Gardosi and Heteroscedastic a

% Relative difference between Gardosi and Quantile b

%

37 959 982 962 -2.4 -0.3

38 1042 969 963 7.0 7.5

39 1116 962 948 13.8 15.1

40 1147 949 918 17.3 19.9

41 1176 937 903 20.3 23.2

42 1216 921 921 24.2 24.3

GA, gestational age; Hetero, heteroscedastic

a Relative difference was calculated using the range as [(Gardosi–Hetero)/Gardosi] *100%

b Relative difference was calculated using the range as [(Gardosi–Quantile)/Gardosi] *100%

3) i will consider in the reference list and in the discussion the paper of Ghi et al JUM 2016 that similarly also used father characteristics in the construction of the customized mode

Response: We originally omitted this study because it didn’t report EFW or birthweight which was the focus of our study; however, we have now added this reference to the discussion. Page 25, new text underlined:

“These findings are similar to findings from the Generation R cohort of EFW in the Netherlands [34] and fetal biometric measurements in an Italian cohort [new reference 35] although…”

Reviewer #2: The authors use longitudinal fetal weight measurements they obtained in the NICHD Fetal Growth Studies to assess some of the assumptions of the Gardosi’s customized chart which assumes that i) standard deviation is a fixed proportion of the mean, and that ii) the effect of maternal characteristics is proportional throughout gestation and affects all percentiles of the distribution. Specifically, the authors evaluated the normality and constant coefficient of variation (CV) assumptions and propose the hetroscedastic and quantile regressions based percentiles as an alternative.

Major:

1) Although the attention to the non-normality of the fetal growth data is warranted, the WHO and PRB/NICHD standards already proposed the use of quantile regression. Moreover, the PRB/NICHD standard questioned the proportionality of the effects of maternal characteristics and showed differential effects on specific percentiles. The paper should put these results in perspective and perhaps somehow tone down claims of novelty.

Response: We agree with the reviewer that others have used quantile regression and questioned the proportionality assumption of the Gardosi customization method. The novelty of our analysis is the in-depth examination and explaining whether Gardosi assumptions hold. We have clarified this point in the paper and added the WHO and PRB references (new text underlined):

“We performed an in-depth examination of the statistical assumptions of the Gardosi customization method.” (p. 23)

“ Quantile regression was used to create the WHO fetal growth charts and also for a customized fetal growth reference in an African-American population. (new references 30, 31; p. 24)

2) Comparison of customized and non-customized standards were also evaluated for prediction of adverse outcomes and the authors miss to acknowledge and discuss previous work (https://pubmed.ncbi.nlm.nih.gov/31006913/).

Response: While we do recognize the important contribution of the Kabiri paper, our goal was not to compare customized and non-customized standards, as we agree that this subject has been extensively studied. Our goal was to compare the statistical methods of customization. We have now added the Kabiri reference to the discussion (new reference 30) as outlined in response to Reviewer 2, Comment 1 above and edited the Discussion as follows (p. 24, new text underlined):

“In the study by Kabiri et al, a customized fetal growth reference based on quantile regression did not improve prediction of perinatal morbidity compared with ultrasound references. While in the present cohort the model also did not show significant improvement in terms of birthweight prediction, it is expected that as more data from controlled studies become available, the merits of flexible models compared to linear regression-based models could be better evaluated in the context of birthweight customization.”

3) Studying the behavior of the mean and SD only answers questions about the constant CV, but not about the normality. This should better emphasized the paper.

Response: The reviewer is correct that the reported evidence based on the mean and the SD and the bin-specific percentiles do not provide sufficient evidence toward normality as the reason for departure could be due to the violation of constant CV assumption. We further investigated the assumption of normality by checking the residuals from the model fits for the Gardosi and the heteroscedastic models. The quantile regression does not assume normality and hence it is not included in the investigation. The residuals do not show any glaring departure from normality. We have now added this information to the results (p. 18) and in a new s2 Fig.

4) For the assessment of normality, the authors compare the Gardosi percentile with the percentiles generated empirically (for each sub-interval). This does not really answer the question, as the difference between the two values may also be the result of violation of the constant CV (proportionality) assumption. Other contributing factors could be the different datasets involved (Gardosi uses all the avalble data set; empirical uses a dataset in a given sub-interval).

Response: Our goal was not really to assess normal or abnormal. Rather, we wanted to examine how robust the Gardosi estimates were. We agree that it doesn’t say anything conclusive about normality which is why we checked the residuals and have now added to the paper as outlined in response to Reviewer 2, comment 3 above.

5) In Fig 1, we the black line (and dots) for Gardosi model are missing but shown in the legend.

Response: That part of the legend was indicating that the lines are from the models while the dots are the empirical observations. We have removed that information from the figure itself to avoid confusion and added to the figure description. (p. 13)

“The lines are from the models while the points are empirical observations.”

6) The authors noted that “In Fig 2…. If the Gardosi assumption of constant CV was satisfied the standard deviation would fall on the line with constant slope.” This can be true provided that data points in each interval are sufficiently large. It’s important that the authors also give number of data points in each interval.

Response: We have now added the sample size in each group in a footnote. (p. 13)

”The sample size of each group is 5, 25, 85, 292, 668, 822, 350, and 41 for the point representing the grouped bins from smallest to largest predicted birthweight, respectively.” Some of the points on either edge are based on fewer sample points so we also added a new line (red line) illustrating the constant coefficient variation assumption per the Gardosi model. As you can see, the bulk of the points do not fall where one would expect them to be under the Gardosi assumption. (revised Fig 2; revised legend p. 13)

________________________________________

6. PLOS authors have the option to publish the peer review history of their article. If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Giuseppe Rizzo

Reviewer #2: No

________________________________________

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Journal Requirements

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Response: The manuscript has been revised according to journal style requirements.

2. Thank you for including your ethics statement: "IRB approval was obtained at all institutions as well as the NIH #09-CH-N152 on December 2009. Participants gave written informed consent prior to collection of data."

For studies reporting research involving human participants, PLOS ONE requires authors to confirm that this specific study was reviewed and approved by an institutional review board (ethics committee) before the study began. Please provide the specific name of the ethics committee/IRB that approved your study, or explain why you did not seek approval in this case.

Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the “Ethics Statement” field of the submission form (via “Edit Submission”).

For additional information about PLOS ONE ethical requirements for human subjects research, please refer to http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research.

Response: IRB approval was received before the study began. The Methods section has been edited with the information in the ethics statement (p. 5, new text underlined):

“Institutional review board approval was obtained at all participating sites as well as the NIH (IRB approval #09-CH-N152) on December 2009 prior to the study beginning. All participants provided informed consent prior to data collection.”

3. Thank you for stating the following financial disclosure:

This research was supported, in part, by the Division of Population Health Research, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health; and, in part, with Federal funds for the NICHD Fetal Growth Studies – Singletons (Contract Numbers: HHSN275200800013C; HHSN275200800002I; HHSN27500006; HHSN275200800003IC; HHSN275200800014C; HHSN275200800012C; HHSN275200800028C; HHSN275201000009C); and in part, with Federal funds for the Consortium on Safe Labor (Contract Number HHSN267200603425C). KLG has contributed to this work as part of her official duties as an employee of the United States Federal Government.

Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

Response: The Role of Funder statement has been added to the cover letter.

4. Thank you for stating the following in the Acknowledgments Section of your manuscript: This research was supported, in part, by the Division of Population Health Research, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health; and, in part, with Federal funds for the NICHD Fetal Growth Studies – Singletons (Contract Numbers: HHSN275200800013C; HHSN275200800002I; HHSN27500006; HHSN275200800003IC; HHSN275200800014C; HHSN275200800012C; HHSN275200800028C; HHSN275201000009C); and in part, with Federal funds for the Consortium on Safe Labor (Contract Number HHSN267200603425C). KLG has contributed to this work as part of her official duties as an employee of the United States Federal Government. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: This research was supported, in part, by the Division of Population Health Research, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health; and, in part, with Federal funds for the NICHD Fetal Growth Studies – Singletons (Contract Numbers: HHSN275200800013C; HHSN275200800002I; HHSN27500006; HHSN275200800003IC; HHSN275200800014C; HHSN275200800012C; HHSN275200800028C; HHSN275201000009C); and in part, with Federal funds for the Consortium on Safe Labor (Contract Number HHSN267200603425C). KLG has contributed to this work as part of her official duties as an employee of the United States Federal Government. Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

Response: As federal employees, we are required to disclose funding on all published manuscripts. I have removed from the manuscript and added to the cover letter as instructed, but please make sure that this information is included with the manuscript itself.

5. We noted in your submission details that a portion of your manuscript may have been presented or published elsewhere. Please clarify whether this conference proceeding or publication was peer-reviewed and formally published. If this work was previously peer-reviewed and published, in the cover letter please provide the reason that this work does not constitute dual publication and should be included in the current manuscript.

Response: To clarify, there was no abstract formally published for this conference proceeding.

6. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a. If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b. If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

Response: We have submitted the data and accompanying files to NICHD BRADS: https://brads.nichd.nih.gov/

7. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

Response: We have submitted the data and accompanying files to NICHD BRADS. The administrators will notify me when the work is complete (estimated mid-January) and I will notify you when the data is available.

8. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

Response: As the data are not a core part of the research being presented in our study, we have removed this statement from the methods (p. 18).

9. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well.

Response: This information has been added to the Methods section (p. 5):

“Institutional review board approval was obtained at all participating sites as well as the NIH (IRB approval #09-CH-N152) on December 2009 prior to the study beginning. All participants provided written informed consent prior to data collection.”

10. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: : http://journals.plos.org/plosone/s/supporting-information

Response: Captions for our Supporting Information files have been added at the end of our manuscript. We have also updated in-text citations to match accordingly.

Attachment

Submitted filename: Custom response to reviewers 1.23.2023.docx

Decision Letter 1

Quetzal A Class

23 Feb 2023

A new method for customized fetal growth reference percentiles

PONE-D-22-23564R1

Dear Dr. Grantz,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Quetzal A. Class, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Dear Authors,

Thank you for your dedicated responses to concerns raised by the reviewers and myself. There is one minor change that can be addressed during the editing process -- an incorrect citation as pointed out by reviewer 2 -- but otherwise we accept your manuscript for publication.

Thank you,

Quetzal Class

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The manuscript was revised successfully and al the queries were properly addressed. Congratulations !

Reviewer #2: The authors have address most of my questions. There is one minor inconsistency to address, and the authors can be entrusted to address without delaying the acceptance of the paper.

1) To my initial point #1 the authors agree to mention other growth standards that have use quantile regression and questioned the normality assumption. They cited the WHO standard and mentioned the PRB/NICHD standard but for the latter the reference is incorrect. It should be: https://pubmed.ncbi.nlm.nih.gov/29422207/. The Kabiri et al reference is for the study comparison of standards for prediction of neonatal outcomes, as mentioned in the discussion.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Giuseppe Rizzo

Reviewer #2: No

**********

Acceptance letter

Quetzal A Class

7 Mar 2023

PONE-D-22-23564R1

A new method for customized fetal growth reference percentiles

Dear Dr. Grantz:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Quetzal A. Class

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Flowchart for study participants included in analysis.

    From the NICHD Fetal Growth Studies–Singletons.

    (DOCX)

    S2 Fig. Residuals from the model fits.

    The residuals from the model fits for the Gardosi and the heteroscedastic models did not show any glaring departure from normality. The quantile regression does not assume normality and hence it was not included.

    (EPS)

    S1 Table. Equations to calculate the percentiles for the Gardosi, heteroscedastic and quantile regression models.

    (DOCX)

    S2 Table. Model characteristics for Pairs of weeks.

    (XLSX)

    S3 Table. Customization coefficients for customized three models with the addition of paternal height and weight.

    (DOCX)

    S4 Table. Comparison of model performance for the three different methods in detecting SGA and LGA with morbidity in the NICHD Fetal Growth Studies–Singletons (N = 2,288).

    (DOCX)

    Attachment

    Submitted filename: Custom response to reviewers 1.23.2023.docx

    Data Availability Statement

    Data and accompanying files for the NICHD Fetal Growth Study are available through NICHD BRADS, https://brads.nichd.nih.gov/. The Consortium on Safe Labor study data are publicly available through the NICHD Data and Specimen Hub (DASH) https://dash.nichd.nih.gov/.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES